|
Werwolf Therapeutics ، Inc. (Howl) DCF تقييم |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Werewolf Therapeutics, Inc. (HOWL) Bundle
استكشف Outlook المالي في Werwolf Therapeutics ، Inc. (Howl) مع حاسبة DCF سهلة الاستخدام! أدخل توقعاتك على النمو والهوامش والمصروفات لتحديد القيمة الجوهرية في شركة Werewolf Therapeutics ، Inc. (Howl) وتعزيز استراتيجية الاستثمار الخاصة بك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 16.4 | 19.9 | 1.9 | 1.6 | 1.3 | 1.1 | .9 | .7 |
| Revenue Growth, % | 0 | 0 | 0 | 21.6 | -90.55 | -17.24 | -17.24 | -17.24 | -17.24 | -17.24 |
| EBITDA | -14.3 | -49.2 | -51.3 | -32.5 | -64.0 | -.3 | -.3 | -.2 | -.2 | -.1 |
| EBITDA, % | 100 | 100 | -312.79 | -162.79 | -3397.61 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .8 | .7 | 2.5 | 1.8 | 1.8 | 1.0 | .8 | .7 | .6 | .5 |
| Depreciation, % | 100 | 100 | 15.3 | 8.85 | 96.23 | 64.08 | 64.08 | 64.08 | 64.08 | 64.08 |
| EBIT | -15.0 | -50.0 | -53.8 | -34.2 | -65.9 | -.3 | -.3 | -.2 | -.2 | -.1 |
| EBIT, % | 100 | 100 | -328.09 | -171.63 | -3493.85 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 92.6 | 157.5 | 129.3 | 134.3 | 112.2 | 1.6 | 1.3 | 1.1 | .9 | .7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 6.9 | 1.4 | .0 | .8 | .6 | .5 | .4 | .4 |
| Account Receivables, % | 100 | 100 | 42.24 | 6.77 | 0 | 49.8 | 49.8 | 49.8 | 49.8 | 49.8 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .6 | .5 | .4 | .4 | .3 |
| Inventories, % | 100 | 100 | 0.000012194378 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.0 | 2.0 | 1.2 | 1.3 | 3.0 | 1.0 | .8 | .7 | .6 | .5 |
| Accounts Payable, % | 100 | 100 | 7.44 | 6.7 | 161.01 | 62.83 | 62.83 | 62.83 | 62.83 | 62.83 |
| Capital Expenditure | -.6 | -.5 | -3.6 | -.8 | -.3 | -.1 | -.1 | -.1 | -.1 | -.1 |
| Capital Expenditure, % | 100 | 100 | -22.02 | -3.86 | -13.47 | -7.87 | -7.87 | -7.87 | -7.87 | -7.87 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -14.9 | -49.8 | -51.6 | -34.2 | -65.9 | -.3 | -.3 | -.2 | -.2 | -.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -13.7 | -48.5 | -60.4 | -27.5 | -61.3 | -2.9 | .5 | .4 | .4 | .3 |
| WACC, % | 15.73 | 15.76 | 15.35 | 15.81 | 15.81 | 15.69 | 15.69 | 15.69 | 15.69 | 15.69 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 2 | |||||||||
| Present Terminal Value | 1 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -101 | |||||||||
| Equity Value | 101 | |||||||||
| Diluted Shares Outstanding, MM | 44 | |||||||||
| Equity Value Per Share | 2.30 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled real HOWL financial data.
- Authentic Data: Historical performance metrics and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs affect Werewolf Therapeutics’ valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Design: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life HOWL Financials: Pre-filled historical and projected data for Werewolf Therapeutics, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Werewolf Therapeutics’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Werewolf Therapeutics’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Werewolf Therapeutics, Inc. (HOWL) preloaded data.
- 2. Modify Assumptions: Adjust essential inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation outcomes.
- 5. Present with Confidence: Deliver professional valuation insights to bolster your decision-making process.
Why Choose This Calculator for Werewolf Therapeutics, Inc. (HOWL)?
- Accurate Data: Utilize real Werewolf Therapeutics financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations streamline your process, avoiding the need to begin from scratch.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and step-by-step guidance cater to users of all experience levels.
Who Should Use This Product?
- Investors: Accurately assess Werewolf Therapeutics, Inc.'s (HOWL) fair value prior to making investment decisions.
- CFOs: Utilize a professional-grade DCF model for comprehensive financial reporting and analysis.
- Consultants: Easily customize the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices utilized by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies specific to the pharmaceutical industry.
What the Template Contains
- Pre-Filled Data: Includes Werewolf Therapeutics’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Werewolf Therapeutics’ profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.